AsianScientist (Oct. 8, 2013) – PeptiDream Inc., a Tokyo-based pharmaceutical company, and Ipsen, a global specialty driven pharmaceutical group, today announced that they have expanded the scope of their April 2013 research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen.
The existing collaboration, which combines PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D, will now be extended in scope to enable further therapeutic peptide candidates to enter R&D for additional serious endocrinologic disease.
The details of the financial terms of the expanded agreement are not disclosed but are based on those of the existing collaboration. In exchange for worldwide rights to each therapeutic peptide resulting from the collaboration, Ipsen will pay all R&D and commercialization costs.
PeptiDream will receive royalties on worldwide sales; or have the right to opt-in at predefined stages to support Japan development costs of each new candidate for royalty free commercial rights in that territory. In the latter circumstance, PeptiDream would also forego royalty income for ex-Japan sales.
“This expanded partnership with Ipsen to discover novel therapeutic peptides for serious disease reinforces the positive collaborative relationship with Ipsen and further underlines the status of PeptiDream as a major force in therapeutic peptide discovery in the pharmaceutical industry worldwide,” said Patrick Reid, Ph.D., Chief Scientific Officer and Head of PeptiDream’s discovery programs.
——
Source: Ipsen.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
